Poster Presentations Session II
Poster Presentations Session II Monday, 6 November 2017
POSTERS SET-UP: 15:30 - 15:45
POSTERS DISPLAY HOURS: 15:45 - 19:30
POSTER AUTHOR DISCUSSION: 18:30 - 19:30
POSTERS DISMANTLE: 19:30


Poster display locations are shown below the poster codes
HEALTH SERVICES - Clinical Outcomes Studies
PHS1
A1
ASSESSMENT OF KNOWLEDGE, ATTITUDE AND COMMON BARRIERS TOWARDS REPORTING ADVERSE DRUG REACTIONS BY PUBLIC IN MALAYSIA
Arief M1, Bheemavarapu H2, Khan A3, Ahmad A1, Khan MU4, Saleem F5, Hassali MA6
1UCSI University, Kuala Lumpur, Malaysia, 2Talla Padmavati college of pharmacy, Warangal, India, 3Tech Observer, New Delhi, India, 4University of Sydney, Sydney, Australia, 5University of Balochistan, Quetta, Pakistan, 6Universiti Sains Malaysia, Penang, Malaysia

PHS2
A2
A COST-EFFECTIVENESS ANALYSIS OF A PHYSICIAN-IMPLEMENTED, MEDICATION SCREENING TOOL IN OLDER HOSPITALISED PATIENTS IN IRELAND
O'Brien G1, O'Mahony D2, Gillespie P3, Walshe V4, Mulcahy M1, O'Connor M2, O'Sullivan D1, Gallagher J1, Byrne S1
1University College Cork, Cork, Ireland, 2Cork University Hospital, Cork, Ireland, 3National University of Ireland Galway, Galway, Ireland, 4Health Service Executive, Cork, Ireland

PHS3
A3
INVESTIGATION OF DEMOGRAPHIC DIFFERENCES FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH AND WITHOUT TYPE 2 DIABETES
Ruban C1, Blanchette CM2, Howden R3, Kowalkowski M4, Marino J1, Saunders W5
1University of North Carolina Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA, 3University of North Carolina at Charlotte, Charlotte, NC, USA, 4Levine Cancer Institute, Charlotte, NC, USA, 5UNC Charlotte College of Health and Human Services – Health Informatics, Charlotte, NC, USA

PHS4
A4
COMPREHENSIVE KNOWLEDGE AND UPTAKE OF CERVICAL CANCER SCREENING IS LOW AMONG WOMEN LIVING WITH HIV/AIDS IN NORTHWEST ETHIOPIA
Mersha AG
University of Gondar, Gondar, Ethiopia

PHS5
A5
REPORT OF LOW DENSITY LIPOPROTEIN (LDL) LEVELS IN PATIENTS DIAGNOSED WHIT HIPERTENSION, DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE IN COLOMBIAN POPULATION
Merchan A1, Acuña L2, Bryón A3, Gutiérrez B4, Sanchez P2, Soler L5, Aschner P6, Isaza D7, Ruiz A6
1Shaio, Bogota, Colombia, 2Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 3HEORT - Health Economics & Outcomes Research Team, Bogota, Colombia, 4HEORT, Bogota, Colombia, 5Risk Management Cordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia, 6Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 7Fundacion Cardio Infantil, Bogota, Colombia

PHS6
A6
CHARACTERIZATION OF LOW DENSITY LIPOPROTEIN (LDL) LEVELS IN PATIENTS DIAGNOSED WITH ARTERIAL HYPERTENSION AND DIABETES IN COLOMBIAN POPULATION IN THE YEAR 2016
Ruiz A1, Acuña L2, Bryón A3, Gutiérrez B4, Sanchez P2, Soler L5, Merchan A6, Aschner P1, Isaza D7
1Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 2Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 3HEORT - Health Economics & Outcomes Research Team, Bogota, Colombia, 4HEORT, Bogota, Colombia, 5Risk Management Cordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia, 6Shaio, Bogota, Colombia, 7Fundacion Cardio Infantil, Bogota, Colombia

PHS7
A7
THE OCCURRENCE AND TERRITORIAL DISTRIBUTION OF ACUTE MYOCARDIAL INFARCTIONS IN HUNGARY
Németh N, Elmer D, Pónusz R, Bánkyné Perjés B, Kerner Á, Boncz I, Endrei D
University of Pécs, Pécs, Hungary

PHS8
A8
OPTIMAL INTERVAL OF ENDOSCOPIC SCREENING BASED ON STAGE DISTRIBUTION OF DETECTED GASTRIC CANCER
Hamashima C1, Narisawa R2, Ogoshi K2, Kato T2, Fujita K3
1National Cancer Center, Tokyo, Japan, 2Niigata Cancer Center Hospital, Niigata, Japan, 3Niigata City Medical Association, Niigata, Japan

PHS9
A9
EFFECT OF PHARMACIST CARE ON MEDICATION ADHERENCE AND CARDIOVASCULAR OUTCOMES AMONG PATIENTS POST-ACUTE CORONARY SYNDROME: A SYSTEMATIC REVIEW
El Hajj M, Jaam M, Awaisu A
Qatar University College of Pharmacy, Doha, Qatar

PHS10
A10
EFFECTIVENESS OF A PHARMACIST-DELIVERED SMOKING CESSATION PROGRAM IN THE STATE OF QATAR: A RANDOMIZED CONTROLLED TRIAL
El Hajj M1, Kheir N1, Al Mulla AM2, Shami R1, Fanous N3, Mahfoud Z4
1Qatar University College of Pharmacy, Doha, Qatar, 2Medicine Department Hamad Medical Corporation, Doha, Qatar, 3The University of Glasgow, Glasgow, UK, 4Weill Cornell Medicine- Qatar, Doha, Qatar

PHS11
A11
ASSOCIATION BETWEEN MONTHLY JOINT REPLACEMENT VOLUME AND PATIENT OUTCOMES
Johnson TJ1, Skowron P1, Winn T1, Hohmann SF2, Glanzman R3
1Rush University, Chicago, IL, USA, 2Vizient, Inc., Chicago, IL, USA, 3Midwest Orthopedics at Rush, Chicago, IL, USA

PHS12
A12
MICROBIOLOGICAL, CHEMICAL ANALYSIS AND COMPARISON OF PUBLIC BATH WATERS IN BARANYA COUNTY BETWEEN 2010-2016
Kapitány R1, Galambos A2, Danku N1, Boncz I1, Pusztafalvi H1
1University of Pécs, Pécs, Hungary, 2Government Office of Baranya County, Pécs, Hungary

PHS13
A13
CLINICAL INERTIA IN TYPE 2 DIABETES MELLITUS: TIME IN POOR GLYCAEMIC CONTROL UNTIL TREATMENT INTENSIFICATION IN PATIENTS ON DPP-4I AND/OR SGLT-2I TREATMENT
Lanzinger S1, Kalscheuer H2, Welp R3, Zimmermann A4, Propp S5, Fasching P6, Wagner S7, Holl RW1
1University of Ulm, Ulm, Germany, 2University Hospital Lübeck, Lübeck, Germany, 3Knappschafts-Krankenhaus Bottrop, Bottrop, Germany, 4Specialized Diabetes Practice, Bad Aibling, Germany, 5Clinical Center Gesundbrunnen, Heilbronn, Germany, 6Wilhelminenspital Vienna, Vienna, Austria, 7Donauisar Clinical Center Deggendorf, Deggendorf, Germany

PHS14
A14
PERSISTENCE AND ADHERENCE TO ORAL ANTIRESORPTIVE THERAPY IN A FRACTURE LIAISON SERVICE: 24-MONTH RESULTS OF A PROSPECTIVE COHORT STUDY
Senay A1, Perreault S1, Delisle J2, Kwon H1, Raynauld J3, Banica A2, Troyanov Y2, Beaumont P2, Giroux M4, Jodoin A2, Laflamme Y2, Leduc S2, MacThiong J2, Malo M2, Maurais G2, Nguyen H4, Parent S2, Ranger P2, Rouleau D2, Fernandes JC2
1Université de Montréal, Montreal, QC, Canada, 2Hôpital du Sacré-Coeur de Montréal, Montreal, QC, Canada, 3Institut de rhumatologie de Montréal, Montreal, QC, Canada, 4Hôpital Jean-Talon, Montreal, QC, Canada

PHS15
A15
GROWTH HORMONE PHARMACOECONOMICS AND PRESCRIPTION DATA FOR CHILDREN OUTPATIENTS IN A REGIONAL GENERAL HOSPITAL
Rinaki E, Petrongonas M, Fragiadaki M, Tzimis L
Chania General Hospital, Chania, Greece

PHS16
A16
A CROSS SECTION STUDY ON PREVALENCE OF NEURO-PSYCHIATRIC DISORDERS AND QUALITY OF LIFE IN POST STROKE PATIENTS
Kiron sS1, Susmitha G2, Saritha M3
1KERALA HEALTH UNIVERSITY, KANNUR, India, 2ACADEMY OF PHARMACEUTICAL SCIENCES, KANNUR, India, 3crescent college of pharmacy, kannur, India

PHS17
A17
HEALTH CARE USE AMONG INCIDENT CASES OF HEART FAILURE: A POPULATION-BASED COHORT STUDY FROM 1997 TO 2010
Perreault S1, de Denus S2, White M2, White-Guay B1, Dorais M3
1Université de Montréal, Montreal, QC, Canada, 2Institut de Cardiologie de Montreal, Montreal, QC, Canada, 3StatSiences Inc,, Notre-Dame-de-l'Ile-Perrot, QC, Canada

PHS18
A18
EFFECTS OF LOW SALT DIET ON GENE EXPRESSION IN DOG HEART
Ren X, Zhang R
Shanxi University of Chinese Medcine, XianYang, China

PHS19
A19
CASE-CONTROL STUDY ON RISK FACTORS FOR CANCER FROM THE EPIDEMIOLOGICAL SURVEY CARRIED OUT ON BENEFICIARIES OF A PRIVATE HEALTH CARE PLAN IN BRAZIL: 10 YEARS OF FOLLOW-UP
Reis Neto JP1, Busch JM1, Stefani S2
1Souza Marques University, Rio de Janeiro, Brazil, 2, Rio de Janeiro, Brazil

PHS20
A20
BETWEEN-HOSPITAL VARIATION OF IN-HOSPITAL MORTALITY AND 30-DAY READMISSIONS IN ACUTE MYOCARDIAL INFARCTION IN PORTUGAL: 2012-2014
Lobo MF1, Azzone V2, Lopes F1, Freitas A1, Costa-Pereira A1, Normand ST3, Teixeira-Pinto A4
1Faculty of Medicine, University of Porto, Porto, Portugal, 2Harvard Medical School, Boston, MA, USA, 3Harvard Medical School and Harvard T.H. Chan School of Public Health, Boston, MA, USA, 4The University of Sydney, Sydney, Australia

PHS21
A21
THE ROLE OF COMMUNITY PHARMACISTS IN PATIENT COUNSELLING AND HEALTH EDUCATION: A SURVEY OF THEIR KNOWLEDGE AND LEVEL OF INVOLVEMENT IN RELATION TO TYPE 2 DIABETES MELLITUS.
Haile KT1, Ayele AA2, Erku dA1, Belachew SA1, Gebresillassie BM2, Tegegn HG1
1University of Gondar, Gondar, Ethiopia, 2University of Gondar, gondar, Ethiopia

HEALTH SERVICES - Cost Studies
PHS22
A22
INTEGRATED CARE SYSTEM FOR HYPERTENSION IN CHINA: WHAT THE COST WILL BE FOR GOVERNMENT? A BUDGET IMPACT ANALYSIS
Sui B, Zhao K, Wang Y, Guo W, Shi L
China National Health Development Research Center, Beijing, China

PHS23
A23
COMPARISON OF COSTS BETWEEN HOSPITAL AND HOME INFUSIONS IN PATIENTS TREATED WITH LARONIDASE
Stewart A1, Hao L2
1Sanofi, Cambridge, MA, USA, 2Sanofi, Bridgewater, NJ, USA

PHS24
A24
COMPARING THE HEALTHCARE COST UTILIZATION OF PAEDIATRIC PATIENTS WITH HAEMOPHILIA A WITH AND WITHOUT INHIBITORS TREATED AT INSTITUTO DE SEGURIDAD SOCIAL DEL ESTADO DE MEXICO Y MUNICIPIOS
Lopez Facundo A1, Mercado Garcia J1, Rodriguez Castillejos C1, Fonseca Zarco A2, Garcia Uranga J2
1ISSEMYM, TOLUCA, Mexico, 2NOVO NORDISK MEXICO SA DE CV, MEXICO CITY, Mexico

PHS25
A25
COMPARISONS OF HEALTHCARE UTILIZATION AND COST IMPACT OF MANAGING TYPE 2 DIABETES ACROSS THE SYSTEM OF CARE IN MEDICARE BENEFICIARIES
Karlsson K, Lam E, Moss J
Sg2, Skokie, IL, USA

PHS26
A26
BURDEN OF ULCERATIVE COLITIS IN JAPAN
Yamabe K1, Kuwabara H1, Inoue S2, Kobayashi M2
1Takeda Pharmaceutical Company Limited, Tokyo, Japan, 2CRECON Medical Assessment Inc., Tokyo, Japan

PHS27
A27
ECONOMIC IMPACT OF ATOPIC DERMATITIS IN ADULTS: A POPULATION STUDY (IDEA STUDY)
Sicras Mainar A1, Carrascosa JM2, Navarro-Artieda R3
1General Practitioner, Badalona, Spain, 2Department of Dermatology, Germans Trias i Pujol University Hospital, Barcelona, Spain, 3Documentación Médica,Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

PHS28
B1
A SYSTEMATIC LITERATURE REVIEW OF THE SOCIETAL COSTS AND CONSEQUENCES OF HEROIN ADDICTION
Kenworthy J1, Ayyub R2, Rtveladze K2, Wright D2, Xia A1, Fordham R3
1Mundipharma International Ltd, Cambridge, UK, 2QuintilesIMS, London, UK, 3University of East Anglia, Norwich, UK

PHS29
B2
DIRECT MEDICAL COSTS IN THE YEAR OF MORTALITY FOR PATIENTS WITH DIABETES: A POPULATION-BASED PATIENT-LEVEL ANALYSIS
Wong CK, Jiao F, Tang EH, Fung CS, Lam CL
The University of Hong Kong, Hong Kong, Hong Kong

PHS30
B3
DIRECT MEDICAL COSTS OF HYPOGLYCEMIA HOSPITALIZATIONS IN THE UNITED STATES
Goyal RK1, Sura SD2, Mehta HB3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2University of Houston, Houston, TX, USA, 3University of Texas Medical Branch, Galveston, TX, USA

PHS31
B4
CHARACTERIZATION AND APPROXIMATION OF THE DIRECT COSTS OF AXIAL AND PERIPHERAL SPONDYLOARTHRITIS IN A CLINICAL MANAGEMENT CENTER IN COLOMBIA
Jauregui E, Gonzalez K, Agudelo C, Aldana C, Muñoz Y
Riesgo de fractura S.A, Bogotá, Colombia

PHS32
B5
HEALTH INSURANCE COST OF MIGRAINE IN HUNGARY: A COST OF ILLNESS STUDY
Oberfrank F1, Donka-Verebes É2, Boncz I3
1Institute of Experimental Medicine, Budapest, Hungary, 2Integra Consulting Zrt., Budapest, Hungary, 3University of Pécs, Pécs, Hungary

PHS33
B6
Economic burden of hospitalized diarrheal disease in Bangladesh
Sarker AR1, Sultana M2, Mahumud RA2, Khan JA3, Meer RV1, Morton A4
1University of Strathclyde, Glasgow, UK, 2International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh, 3Liverpool School of Tropical Medicine, Liverpool, UK, 4University of Strathclyde, Glasgow, Scotland, UK

PHS34
B7
ECONOMIC BURDEN OF HOUSEHOLD FOR TREATING SEVERE PNEUMONIA AMONG UNDER FIVE CHILDREN IN BANGLADESH
Sultana M1, Sarker AR2, Mahumud RA1, Chisti MJ1, Ahmed T1, Alam NH1
1International Centre for Diarrheal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh, 2University of Strathclyde, Glasgow, UK

PHS35
B8
RESOURCE UTILISATION AND RELATED HEALTH CARE COSTS AMONG PATIENTS WITH MULTIPLE MYELOMA WITH ≥ 2 PRIOR LINES OF TREATMENT IN FINLAND: EVALUATION BASED ON FINNISH REAL WORLD DATA FROM AURIA BIOBANK
Kosunen M1, Kurki S2, Snicker K3, Wiik E4
1Medaffcon Oy, Espoo, Finland, 2Auria Biobank, Turku University Hospital and University of Turku, Turku, Finland, 3MedSker Oy, Espoo, Finland, 4Novartis Finland Oy, Espoo, Finland

PHS36
B9
THE EPIDEMIOLOGY OF ADULT IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA (ITP) IN FINLAND: RESOURCE UTILISATION, RELATED COSTS AND HOSPITAL MEDICATION ASSOCIATED WITH THE TREATMENT OF NON-SPLENECTOMISED ADULT ITP BASED ON REAL WORLD DATA FROM AURIA BIOBANK
Kosunen M1, Kurki S2, Snicker K3, Wiik E4
1Medaffcon Oy, Espoo, Finland, 2Auria Biobank, Turku University Hospital and University of Turku, Turku, Finland, 3MedSker Oy, Espoo, Finland, 4Novartis Finland Oy, Espoo, Finland

PHS37
B10
RESOURCE USE, HEALTH CARE COSTS AND BURDEN OF DISEASE IN PATIENTS WITH POLYCYTHEMIA VERA IN FINLAND: EVALUATION BASED ON LEUKOCYTE COUNTS USING FINNISH REAL WORLD DATA FROM AURIA BIOBANK
Kosunen M1, Kurki S2, Snicker K3, Wiik E4
1Medaffcon Oy, Espoo, Finland, 2Auria Biobank, Turku University Hospital and University of Turku, Turku, Finland, 3MedSker Oy, Espoo, Finland, 4Novartis Finland Oy, Espoo, Finland

PHS38
B11
THE BURDEN AND COST OF ILLNESS OF GOUT IN SECONDARY CARE IN ENGLAND
Dakin HL1, Wilkins J2, Hickey DA3
1OPEN Access Consulting (an OPEN Health company), Marlow, UK, 2Harvey Walsh Ltd (an OPEN Health company), Runcorn, UK, 3OPEN Access Consulting (an OPEN Health Company), London, UK

PHS39
B12
SECONDARY CARE RESOURCE UTILIZATION AND COST OF CARE AMONG FINNISH INFLAMMATORY BOWEL DISEASE PATIENTS
Ventola H1, Torvinen S2, Aaltonen J3, Herrala S1, Linna M4, Ylisaukko-oja T1, Voutilainen M5
1MedEngine Oy, Helsinki, Finland, 2Takeda Oy, Helsinki, Finland, 3Takeda, Helsinki, Finland, 4Aalto University, Espoo, Finland, 5Turku University Hospital and University of Helsinki, Turku, Finland

PHS40
B13
THE UK'S BINGE DRINKING CULTURE: LOSING MORE THAN JUST OUR DIGNITY?
Martin RL
Open Access Consulting, London, UK

PHS41
B14
THE COST OF TREATING DIABETIC KETOACIDOSIS IN THE UK: A NATIONAL SURVEY OF HOSPITAL RESOURCE USE
Dhatariya KK, Skedgel CD, Fordham RJ
University of East Anglia, Norwich, UK

PHS42
B15
THE COST OF PRESCRIBING DIRECT ORAL ANTICOAGULANTS (DOACS) – THERE IS A DRUG COST BUT WHAT ELSE?
Kirby A1, Murphy A1, Bradley C1, Browne J2
1University College Cork, Cork, Ireland, 2Cork, Cork, Ireland

PHS43
B16
FRENCH PEOPLE WITH MS AND THEIR CAREGIVERS HAVE TO FINANCIALLY SUPPORT DIRECT NON-MEDICAL COSTS LINKED TO THEIR DISEASE.
van Hille B1, Heinzlef O2, Dourgnon P3, Molinier G4, Chekroun M5, Longin J6
1Merck s.a.s., LYON, France, 2Hôpital de Poissy, Poissy, France, 3IRDES, Paris, France, 4Ligue Française contre la Sclérose en Plaques, PARIS, France, 5carenity.com, Paris, France, 6Merck, LYON, France

PHS44
B17
ECONOMIC EVALUATION FOR ESTABLISHING STROKE UNIT FOLLOWED BY EARLY SUPPORTED DISCHARGE IN EGYPT
Abotaleb A
world health organization, cairo, Egypt

PHS45
B18
CHARACTERIZATION OF HEALTH CARE UTILIZATION AND COST OF HEMOPHILIA A AND B IN REAL-LIFE: A 4-YEAR FOLLOW-UP STUDY IN FINLAND
Ventola H1, Jokelainen J1, Linna M2, Lepäntalo A3, Ylisaukko-oja T1, Lassila R3
1MedEngine Oy, Helsinki, Finland, 2Aalto University, Espoo, Finland, 3Helsinki University Hospital, Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland

PHS46
B19
HEART FAILURE MANAGEMENT: IMPACT OF A NEW HEALTH-CARE ORGANISATION ON READMISSIONS AND COSTS
Bourel G1, Duteil E2, Mahieu N2, Roubille F1, Mercier G1
1CHU Montpellier, Montpellier, France, 2Novartis Pharma, Rueil-Malmaison, France

PHS47
B20
THE COST-EFFECTIVENESS OF SCREENING FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID) IN THE UK NHS NEWBORN BLOODSPOT SCREENING PROGRAMME
Bessey A, Leaviss J, Galvan de la Cruz C, Chilcott J, Wong R
University of Sheffield, Sheffield, UK

PHS48
B21
AN ECONOMIC MODEL TO ESTIMATE THE DIRECT ECONOMIC VALUE OF REDUCING THE SEVERITY OF SEPSIS IN FRENCH AND US HOSPITALS
Paoli CJ1, Coles CN2, Reynolds M1, Blanchet J1, Denham D1, Crouser ED3, Gitlin M2
1Beckman Coulter, Brea, CA, USA, 2BluePath Solutions, Los Angeles, CA, USA, 3The Ohio State University Wexner Medical Center, Columbus, OH, USA

PHS49
B22
COST-EFFECTIVENESS OF INPATIENT REHABILITATION COMPARED TO HOME DISCHARGE FOLLOWING LONGER STAY IN GENERAL OR NEUROLOGICAL WARD, AFTER ADMISSION FOR THE FIRST EVER STROKE IN GREECE
Vellopoulou K1, Kourlaba G2, Vagiona A3, Ntavelis A4, Maniadakis N1
1National School of Public Health, Athens, Greece, 2Collaborative Center of Clinical Epidemiology and Outcomes Research (CLEO), Non-Profit Civil Partnership, Athens, Greece, 3ANAGENNISI Recovery and Rehabilitation Center S.A, Thessaloniki, Greece, 4ANIMUS, Larissa, Greece

PHS50
B23
SCREENING FOR ASYMPTOMATIC ATRIAL FIBRILLATION: ITS EFFECTIVENESS AND COST-EFFECTIVENESS OF REPEATED ECG IN POLAND
Petryszyn P1, Niewinski P1, Piotrowski P1, Staniak A1, Well M2, Ekk-Cierniakowski P3
1Wroclaw Medical University, Wroclaw, Poland, 2Wroclaw Uiversity of Economics, Wroclaw, Poland, 3Warsaw School of Economics, Warsaw, Poland

PHS51
B24
A NOVEL ATRIAL FIBRILLATION EVALUATION MODELLING SOLUTION FOR NHS
Xydopoulos G1, Fordham R1, Khanbai Z2
1University of East Anglia, Norwich, UK, 2Royal Brompton and Harefield Specialist Care, London, UK

PHS52
B25
ONE SIZE DOES NOT FIT ALL: WHAT ARE THE APPROPRIATE SCREENING INTERVALS FOR PEOPLE AT RISK OF DIABETIC RETINOPATHY
Winfield TG1, Thomas R1, Luzio S1, Anderson P1, Dunstan F2, Peter R3, Owens D1
1SWANSEA UNIVERSITY, SWANSEA, UK, 2CARDIFF UNIVERSITY, CARDIFF, UK, 3NEATH PORT TALBOT HOSPITRAL HOSPITAL, SWANSEA, UK

PHS53
B26
: COST-UTILITY ANALYSIS OF ANTIHYPERTENSIVE DOSAGE ADJUSTMENTS BY A PHARMACIST IN A COMMUNITY SETTING
Houde F1, Lachaine J2
1University of Montreal, Montréal, QC, Canada, 2University of Montreal, Montreal, QC, Canada

PHS54
B27
COMPARING COST-EFFECTIVENESS OF A CENTRALIZED VERSUS DECENTRALIZED STROKE CARE SYSTEM: USING PATIENT-LEVEL DATA TO ESTIMATE SHORT- AND LONGTERM EFFECTS
Freriks RD1, Pizzo E2, Luijckx GJ3, Buskens E3, van der Zee D1, Mierau JO1, Lahr MM3
1University of Groningen, Groningen, The Netherlands, 2University College London, London, UK, 3University Medical Center Groningen, Groningen, The Netherlands

PHS55
C1
DISEASE BURDEN OF FRACTURES IN PATIENTS WITH OSTEOPOROSIS IN JAPAN
Fujiwara S1, Umareddy I2, Jaffe D3, Teoh C2, Taguchi Y4
1Hiroshima Atomic Bomb Casualty Council, Hiroshima, Japan, 2Kantar Health, Singapore, Singapore, 3Kantar Health, Tel Aviv, Israel, 4Amgen Astellas BioPharma K.K., Tokyo, Japan

PHS56
C2
BURDEN OF DISEASE, HEALTHCARE PATHWAYS AND COSTS OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS: AN ITALIAN REAL WORLD STUDY ON 10 MILLION INHABITANTS
Piccinni C1, Ronconi G1, Dondi L1, Rossi E2, Pedrini A1, Martini N1
1CORE srl – Collaborative Outcome Research, Casalecchio di Reno (Bologna), Italy, 2CINECA Interuniversity Consortium, Casalecchio di Reno, Italy

PHS57
C3
HEALTHCARE RESOURCE UTILIZATION AND COST OF PATIENTS WITH ACUTE CORONARY SYNDROMES IN TIANJIN, CHINA
Wang Y1, Cong H2, Lu C3, Liu J4, Wu J1
1Tianjin University, Tianjin, China, 22. Tianjin Chest Hospital, Tianjin, China, 33. Tianjin First Center Hospital, Tianjin, China, 4Tianjin Health Insurance Research Association, Tianjin, China

PHS58
C4
COST OF TREATMENT-RELATED ADVERSE EVENTS (TRAES) IN SECOND-LINE (2L) ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): MATCH ADJUSTED INDIRECT COMPARISON (MAIC) OF NIVOLUMAB AND REGORAFENIB
Venkatachalam M1, Stenehjem D2, Parikh ND3, Singh P4, Marett B4, Sill B4, Wisniewski T4, Prakash V5, Shukla P5, Korytowsky B4, Siddiqui MK5
1PAREXEL International, Waltham, MA, USA, 2University of Minnesota, Duluth, MN, USA, 3University of Michigan, Ann Arbor, MI, USA, 4Bristol-Myers Squibb, Princeton, NJ, USA, 5PAREXEL International, Chandigarh, India

PHS59
C5
APPROPRIATE DIAGNOSIS AND TREATMENT AS KEY ELEMENTS TO IMPROVE HEALTH AND RATIONALIZE USE OF RESOURCES FOR OBSESSIVE-COMPULSIVE-TIC-DISORDER
Scalone L1, D'Angiolella LS1, Galentino R2, Servello D3, Dell'Osso BM4, Zanaboni C3, Porta M3, Mantovani LG1
1University of Milano-Bicocca, Monza, Italy, 2IRCCS Galeazzi Hospital, Milan, Italy, 3IRCCS Galeazzi Hospital, Milan, Italy, Milano, Italy, 4University of Milan - Ospedale Policlinico, Milan, Italy

HEALTH SERVICES - Patient-Reported Outcomes & Patient Preference Studies
PHS60
C6
ASSESSMENT OF HYPERTENSION PATIENTS’ ADHERENCE IN BULGARIA – PILOT STUDY
Andreevska K1, Grekova D1, Todorova A2, Madzharov V1, Tsvetkova A3, Petkova V4
1Medical University - Plovdiv, Faculty of Pharmacy, Plovdiv, Bulgaria, 2Medical University - Varna, Faculty of Pharmacy, Varna, Bulgaria, 3Medical University - Varna, Medical College of Varna, Varna, Bulgaria, 4Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria

PHS61
C7
DETERMINATION OF NEEDS AND PRIORITIES IN ORDER TO BETTER ORGANIZATION OF ANTENATAL COURSES
Karácsony I1, Bognár B1, Oláh A2, Szabó L2, Boncz I2, Ferenczy M1, Brantmüller É2, Pakai A3
1University of Pécs, Szombathely, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary

PHS62
C8
EXAMINATION OF ADHERENCY OF HIGH-RISK PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS CARE ESPECIALLY WITH RESPECT TO DIET AND PHYSICAL ACTIVITY
Karácsony I1, Simon M1, Szabó L2, Oláh A2, Boncz I2, Pachner O1, Ipolyi D3, Pakai A4
1University of Pécs, Szombathely, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Kaposvár, Hungary, 4University of Pécs, Zalaegerszeg, Hungary

PHS63
C9
DOES THE STUDY POPULATION AND THE USE OF PROXY RESPONDENT HAVE AN EFFECT ON THE LATENT QUALITY OF LIFE CONSTRUCTS MEASURED BY THE CHU9D AND THE PEDSQLTM 4.0? AN EXPLORATORY FACTOR ANALYSIS
Mpundu-Kaambwa C1, Chen G2, Huynh E3, Russo R4, Ratcliffe J1
1University of South Australia, Adelaide, Australia, 2Monash University, Melbourne, Australia, 3University of South Australia, Sydney, Australia, 4Women's and Children's Health Network, Adelaide, Australia

PHS64
C10
COMPARISON OF ELDERLY CARE RECIPIENTS’ SOCIAL CARE-RELATED QUALITY OF LIFE (SCRQOL) WITH HEALTH RELATED QUALITY OF LIFE (HRQOL) IN JAPAN
Shiroiwa T1, Moriyama Y1, Nakamura H2, Morikawa M3, Fukuda T1
1National Institute of Public Health, Wako, Japan, 2Saitama Prefectural University, Koshigaya, Japan, 3Tsuda University, Tokyo, Japan

PHS65
C11
PARENTAL SATISFACTION WITH MEDICATIONS THERAPY AND PARENTING STRESS AMONG PARENTS WITH ASTHMATIC CHILDREN
Almogbel Y1, Sansgiry SS2
1College of Pharmacy​, Qassim University, Buraidah, Saudi Arabia, 2College of Pharmacy, University of Houston, Houston, TX, USA

PHS66
C12
EASIPRO3 – ENHANCING SATISFACTION WITH PROSTATE CANCER TREATMENT DECISION WITH THE MOBILE HEALTH PROGRAM PROSTANA: A MULTICENTER RANDOMIZED CONTROLLED TRIAL
Vosgerau S1, Urbanski D2, Kollenbach P3, Schöne M4, Gedamke M1, Donatz V1, Bültmann O5, Amelung V2
1Ferring Arzneimittel, Kiel, Germany, 2Institut für angewandte Versorgungsforschung, Berlin, Germany, 3Professional Association of Urologists in Hessen (Berufsverband der Deutschen Urologen, BDU-Hessen), Kassel, Germany, 4Medizinisches Versorgungszentrum für Urologie und Uroonkologie, Speyer, Germany, 5GAIA AG, Hamburg, Germany

PHS67
C13
OLDER ADULTS’ VIEWS ON INCORPORATING LIFE EXPECTANCY IN SCREENING CHOICES – RESULTS FROM A NATIONAL SURVEY USING A DISCRETE-CHOICE EXPERIMENT
Janssen EM1, Bridges JF1, Schoenborn N2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins School of Medicine, Baltimore, MD, USA

PHS68
C14
THE POST-TRAUMATIC STRESS DISORDER AND MEDICATION ADHERENCE ENCOUNTERED AT PATIENTS WITH RHEUMATOID ARTHRITIS
Subtirelu M1, Turcu-Stiolica A2, Vreju F2, Turcu-Stiolica RA2, Neamtu J2
1University of Medicine and Pharmacy, Craiova, Romania, 2University of Medicine and Pharmacy of Craiova, Craiova, Romania

PHS69
C15
IMPACT OF A PHARMACIST-LED INTERVENTION ON THE KNOWLEDGE OF APPROPRIATE USE OF PEAK FLOW METER AND ASTHMA ACTION PLAN AMONG PHARMACY STUDENTS: A SIMULATED PATIENT APPROACH
Ahmad S1, Wong YZ1, Chow CQ1, Yeap BJ1, Wong IX1, Ismail NE2
1MAHSA University, Bandar Saujana Putra, Malaysia, 2MAHSA University, Bandar Saujana Putra, Jenjarom Kuala Langat, Selangor, Malaysia

PHS70
C16
DEVELOPMENT OF A TOOL TO QUANTIFY AN INDIVIDUAL’S HISTORY OF SUN EXPOSURE: QUALITATIVE PHASE OF THE DEVELOPMENT OF THE SUN EXPOSURE QUESTIONNAIRE
Marrel A1, Nadal F2, Guillemin I1, Auges M3, Questel E2, Berdeaux G4
1Mapi, Patient-Centered Outcomes, Lyon, France, 2Pierre Fabre Dermo-cosmetique, Toulouse, France, 3Pierre Fabre, Boulogne-Billancourt, France, 4Pierre Fabre Medicament, Boulogne-Billancourt, France

PHS71
C17
THE EFFECT OF EPILEPSY ON THE BULGARIAN PATIENTS – PILOT STUDY
Petkova V1, Damyanov V1, Dimitrov M2, Naseva E2
1Medical University-Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University - Sofia, Sofia, Bulgaria

HEALTH SERVICES - Health Care Use & Policy Studies
PHS72
C18
WITHDRAWN

PHS73
C19
FINANCIAL GROUP INCENTIVES IMPROVING MEDICATION PERSISTENCE - HEALTH BEHAVIOR ENGINEERING APPROACH
Gebhardt S, Mir Djawadi B
Paderborn University, Paderborn, Germany

PHS74
C20
VALUE BASED HEALTHCARE IN ORTHOPAEDIC SURGERY: AN EVALUATION BASED ON THE ECONOMIST INTELLIGENCE UNIT GLOBAL ASSESSMENT FRAMEWORK
Tavare A1, Boshnakova A2, Pannelay A2, Jayakumar P3
1Oxford University, Oxford, UK, 2Economist Intelligence Unit, London, UK, 3Johnson and Johnson Medical Devices, London, UK

PHS75
C21
ANALYSIS OF HOSPITAL EPISODE STATISTICS TO IDENTIFY HOPSITAL RESOURCE USE DUE TO SKIN CANCER IN IRELAND
Gorry C1, Barry M1, McCullagh L2
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College, Dublin, Ireland

PHS76
WITHDRAWN

PHS77
C22
DOES THE EARLY BIRD CATCH THE WORM: EARLY CANCER DETECTION AND SURVIVAL IN THE UK
Squirrell D
Open Health, London, UK

PHS78
C23
REAL WORLD DATA ANALYSIS OF A PATIENT-TAILORED, POST-DISCHARGE SUPPORT PROGRAM FOR PATIENTS UNDERGOING AN OSTOMY SURGERY IN LOWERING READMISSIONS AND EMERGENCY ROOM VISITS
Rojanasarot S1, Gardner-Westmark M2, Au A2, Carlson AM3
1College of Pharmacy, University of Minnesota, Minneapolis, MN, USA, 2Coloplast Corporation, Minneapolis, MN, USA, 3Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

PHS79
C24
INVOLVEMENT OF COMMUNITY PHARMACISTS IN PUBLIC HEALTH PRIORITIES: A MULTI-CENTER DESCRIPTIVE SURVEY IN ETHIOPIA
Mersha AG, Erku DA
University of Gondar, Gondar, Ethiopia

PHS80
C25
TOOLS FOR IMPROVING EFFICIENCY IN CLINICAL MANAGEMENT AND SAFETY OF HYPERTENSIVE PATIENTS. EFIGIE-HTA PROJECT
Hidalgo A1, Orozco-Beltrán D2, Górriz JL3, Ferrer D4, Sabaté N5, Martell N6, Muñiz O7, Galgo A8
1University of Castilla-La Mancha, Toledo, Spain, 2Cabo Huertas Health Centre, San Juan de Alicante, Spain, 3Hospital Clínico Universitario, Valencia, Spain, 4Institut Català de la Salut, Tarragona, Spain, 5Hospital Vall d´Hebron, Barcelona, Spain, 6Hospital Clínico Universitario, Madrid, Spain, 7Hospital Universitario Virgen del Rocío, Sevilla, Spain, 8Centro de Salud Espronceda, Madrid, Spain

PHS81
C26
THE COORDINATED MANAGEMENT OF PATIENT WITH MENTAL ILLNESS IN SPAIN BY HOSPITAL, PRIMARY CARE AND COMMUNITY PHARMACISTS (3PH), A RESOURCE OPTIMIZATION MODEL
Parramon M1, Moya P2, Martinez MJ3
1Otsuka Pharmaceutical, Barcelona, Spain, 2Complejo Hospitalario de Toledo, Toledo, Spain, 3Toledo College of Pharmacy, Toledo, Spain

PHS82
C27
REAL WORLD TREATMENT PATTERNS IN METASTATIC AND/OR UNRESECTABLE GASTRIC CANCER PATIENTS IN RUSSIA
Tjulandin SA1, Sholokhova E2, Ivanova JI3, Cheng WY4, Schmerold LM3, Thompson-Leduc P5, Novick D6
1N. N. Blokhin Cancer Research Center, Moscow, Russian Federation, 2Lilly Pharma, Moscow, Russian Federation, 3Analysis Group, Inc., New York, NY, USA, 4Analysis Group, Inc., Boston, MA, USA, 5Groupe d'analyse, Ltée, Montréal, QC, Canada, 6Eli Lilly and Company, Windlesham, Surrey, UK

PHS83
D1
BURDEN OF ENDOMETRIOSIS AND RELATED SYMPTOMS IN A NATIONWIDE HEALTH PLAN WITH 2 MILLION MEMBERS
Weil C1, Chodick G2, Shalev V2, Eisenberg VH2
1Maccabi Healthcare Services, Tel Aviv, Israel, 2Maccabi Healthcare Services and Tel Aviv University, Tel Aviv, Israel

PHS84
D2
BRIDGING THE GAP BETWEEN INTERNATIONAL STANDARDS OF QUALITY OF CARE AND PRACTICES IN THE INPATIENT UNIT OF THE NATIONAL TB CONTROL CENTER IN ARMENIA
Truzyan N, Musheghyan L, Grigoryan Z, Petrosyan V
American University of Armenia, Yerevan, Armenia

PHS85
D3
THE FLOW OF EU-28 COUNTRY CLUSTERS IN TERMS OF INFECTIOUS AND CHRONIC DISEASES DURING A REFUGEE CRISIS
Cinaroglu S1, Baser O2
1Hacettepe University, Ankara, Turkey, 2Columbia University and STATinMED Research, New York, NY, USA

PHS86
D4
EFFECT OF PHARMACEUTICAL CARE INTERVENTION ON WELL-BEING INDEX OF TYPE 2 DIABETES OUTPATIENTS IN A TERTIARY HOSPITAL IN SOUTHEAST NIGERIA
Ogbonna BO1, Oparah A2
1Nnamdi Azikiwe University Awka, Benin, Nigeria, 2University of Benin, Benin City, Nigeria

PHS87
D5
COSTS AND EFFECTIVENESS OF AN INTEGRATED CARE INTERVENTION FOR MUSCLE-SKELETAL DISEASES TRANSITION FROM PRIMARY CARE TO SPECIALIZED HOSPITAL CARE
Arrospide A1, Larrañaga I1, Soto-Gordoa M1, Barandiaran A2, San Vicente R2, Ibarrondo O2, Mar J1
1Integrated Health Organisation Alto Deba - Osakidetza, Arrasate, Spain, 2Integrated Health Organisation Goierri Alto Urola - Osakidetza, Zumarraga, Spain

PHS88
D6
TREATMENT PATTERNS AND RESOURCE USE OF TYPE 2 DIABETES PATIENTS MANAGED ON INSULIN IN ENGLAND – RESULTS OF A DELPHI PANEL
Sowemimo B1, Paul E2, Soscia M1, Chapman A3, Mason N3
1Merck Sharp & Dohme Limited, Hoddesdon, UK, 2Merck Sharp & Dohme UK, Hoddesdon, UK, 3BresMed, Sheffield, UK

PHS89
D7
ANALYSING UPTAKE OF NEW MEDICINE SERVICE IN ENGLISH COMMUNITY PHARMACIES
Stanway VE, El-Ghannam M, Murphy EM
Cogora, London, UK

PHS90
D8
WHAT UNDERLIES THE OBSERVED HOSPITAL VOLUME-OUTCOME RELATIONSHIP?
Huguet M1, Perrier L2, Joutard X3, Ray-Coquard I2
1University of Lyon, Lyon, France, 2Cancer Centre Léon Bérard, Lyon, France, 3Aix Marseille University, Aix-en-Provence, France

PHS91
D9
PRE-HOSPITAL PAIN RELIEF TREATMENT IN PATIENTS WITH MUSCULOSKELETAL INJURIES EXPERIENCING MODERATE TO SEVERE PAIN IN MEDICAL EMERGENCIES
Xia A1, Nokela M2, Liebmeier M1, Szende A3, Colman S4
1Mundipharma International Ltd, Cambridge, UK, 2Covance Market Access Services, Solna, Sweden, 3Covance, Leeds, UK, 4Covance Market Access, Sydney, Australia

PHS92
D10
COST CONTAINMENT AND PRIVATISATION OF PHARMACEUTICAL CARE IN GREECE: A REVIEW OF POLICY REFORMS UNDER THE MEMORANDUMS’ REQUIREMENTS
Yfantopoulos J, Chantzaras A, Constantopoulos A
University of Athens, ATHENS, Greece

PHS93
D11
INTEGRATED CARE MODELS IN GERMANY – POTENTIAL MARKET ACCESS ROUTE FOR MEDICAL DEVICES?
Dröschel D1, Vollmer L2, Walzer S2
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany

PHS94
D12
HETEROGENEITY IN GP CONSULTATION COSTS IN HEALTH TECHNOLOGY ASSESSMENTS: EXPLANATIONS AND IMPLICATIONS.
Kelleher D1, O'Neill C2
1The National University of Ireland, Galway, Galway, Ireland, 2Queen's University Belfast, Belfast, UK

PHS95
D13
SURVEILLANCE STATUS, DIAGNOSTIC ACCURACY AND SURVIVAL OF THE NATIONAL LIVER CANCER SURVEILLANCE PROGRAM
Tchoe H1, Kwon J2, Shin S3, Lee J4, Suh J5, Lee J6, Yu E5
1National Evidence-based Healthcare Collaborating Agency(NECA), Seoul, Korea, Republic of (South), 2Kyungpook National University, Daegu, Korea, Republic of (South), 3National Evidence based Health-care Collaborating Agency, Seoul, Korea, Republic of (South), 4Seoul National University Hospital, Seoul, Korea, Republic of (South), 5National Evidence based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South), 6National Evidence-based Healthcare Collaborating Agency, Seoul, Korea, Republic of (South)

PHS96
D14
PRESCRIBING PATTERN ALONG WITH PHARMACOECONOMIC EVALUATION IN PRIMARY HEALTH CARE FACILITIES NEPAL
Baral SR
Gorkhali Pharmacy, Bharatpur, Nepal

PHS97
D15
ESTIMATED CLINICAL IMPACT OF TWO ONCOLOGIC DRUG SHORTAGES
De Weerdt E, Simoens S, Casteels M, Huys I
KU Leuven, Leuven, Belgium

PHS98
D16
POLYPHARMACY AND INTERACTIONS - WHAT IS A PHARMACIST ROLE?
Snopkova M1, Szmicsekova K1, Sukel O2
1Comenius University, Faculty of Pharmacy, Bratislava, Slovakia, 2Slovak Chamber of Pharmacists, Bratislava, Slovakia

PHS99
D17
UNMET PHARMACEUTICAL NEEDS DURING THE ECONOMIC CRISIS IN GREECE
Yfantopoulos J1, Chantzaras A1, Ollandezos M2
1University of Athens, ATHENS, Greece, 2PANHELLENIC ASSOCIATION OF PHARMACEUTICAL INDUSTRY, ATHENS, Greece

PHS100
D18
THE EFFECTS OF THE ECONOMIC CRISIS ON HEALTH STATUS AND HEALTH INEQUALITIES IN GREECE
Chantzaras A, Yfantopoulos J
University of Athens, ATHENS, Greece

PHS101
D19
ASSESSING RACIAL DISPARITY IN PALLIATIVE CARE CONSULTATION AND THE IMPACT OF PALLIATIVE CARE CONSULTATION ON HOSPICE: A MULTI-HOSPITAL ANALYSIS
Johnson TJ1, Walton SM2, Fister E1, Levine S1, Baron A3, O'Mahony S4
1Rush University, Chicago, IL, USA, 2University of Illinois at Chicago, Chicago, MA, USA, 3University of Chicago, Chicago, IL, USA, 4Rush University Medical Center, Chicago, IL, USA

PHS102
D20
DETECTION AND MANAGEMENT OF DIABETES IN ENGLAND: RESULTS FROM THE HEALTH SURVEY FOR ENGLAND.
Xiao M1, O'Neill C2
1National University of Ireland, Galway, Galway, Ireland, 2Queen's University Belfast, Belfast, UK

PHS103
D21
UNMET HEALTHCARE NEEDS DUE TO FINANCIAL REASONS IN TIMES OF AUSTERITY
Zavras D, Naoum P, Athanasakis K, Kyriopoulos J, Pavi E
National School of Public Health, Athens, Greece

PHS104
D22
COMPARISON OF COSTS AND CARE OF LUNG CANCER PATIENT AT THE END-OF-LIFE IN GERMANY DEPENDING ON THE TIME OF SURVIVAL AFTER DIAGNOSIS
Walter J1, Tufman A2, Holle R3, Schwarzkopf L4
1Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany, 2Hospital of the Ludwig-Maximilians-University (LMU) Munich, Munich, Germany, 3Helmholtz Zentrum München - German Research Center for Environmental Health (GmbH), Neuherberg, Germany, 4Helmholtz Zentrum Munchen, Neuherberg, Germany

PHS105
D23
MEASURING THE INTENSITY OF CARE COORDINATION FOR BLOOD CANCER PATIENTS IN FRANCE.
Mercier G1, Duflos C1, Kanouni T2, Chevalier J3, Thevenon J3, Cartron G2
1CHU Montpellier, Montpellier, France, 2CHU de Montpellier, Montpellier, France, 3Janssen-Cilag, Issy-les-Moulineaux, France

PHS106
D24
ASSESSING THE UTILIZATION OF DIABETIC NON-SMALL CELL LUNG CANCER PATIENTS COMPARED TO NON-SMALL CELL LUNG CANCER PATIENTS
Ruban C1, Blanchette CM2, Howden R3, Kowalkowski M4, Marino J1, Saunders W5
1University of North Carolina Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA, 3University of North Carolina at Charlotte, Charlotte, NC, USA, 4Levine Cancer Institute, Charlotte, NC, USA, 5UNC Charlotte College of Health and Human Services – Health Informatics, Charlotte, NC, USA

PHS107
D25
RESOURCE UTILIZATION AND DISAGGREGATED COST ANALYSIS FOR INITIAL TREATMENT OF MELANOMA
Look Hong NJ1, Cheng SY2, Wright FC1, Petrella TM1, Mittmann N3
1University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Cancer Care Ontario, Toronto, ON, Canada

PHS108
D26
COST OF HOSPITALIZATIONS FOR NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE IN FRANCE IN 2014: A PMSI DATABASE ANALYSIS
Lafuma A1, Emery C2, Bureau I3, Chiron R4, Stahl J5
1Cemka-Eval, Bourg La Reine, France, 2Cemka, Bourg La Reine, France, 3Cemka-Eval, Bourg la Reine, France, 4CHU de Montpellier, Montpellier, France, 5CHU de Grenoble, La Tronche, France

PHS109
D27
DIALYSIS STATUS IN PATIENTS WITH CHRONIC KIDNEY DISEASE IN KOREA: BASED ON 12-YEARS NATIONAL SAMPEL COHORT DATABASE
Jung S1, Ha J2, Jang EJ3, Sohn HS4
1Sookmyung Women's University, Seoul, Korea, Republic of (South), 2CHA university, Seongnam-si, Korea, Republic of (South), 3Andong National University, Andong-si, Korea, Republic of (South), 4CHA University, Seongnam-si, Korea, Republic of (South)

PHS110
E1
SOCIAL AND FINANCIAL IMPACT OF DRAVET SYNDROME
Irwin J1, Lagae L2, Gibson E3, Battersby A3
1Zogenix International Limited, Maidenhead, UK, 2University Hospitals KU Leuven, Leuven, Belgium, 3Wickenstones Ltd, Oxfordshire, UK

PHS111
E2
HOSPITALISATIONS AMONG A COHORT OF PATIENTS WITH HEART FAILURE VERSUS AN AGE- AND SEX-MATCHED COHORT WITHOUT HEART FAILURE IN ENGLAND: A COMPARATIVE STUDY USING CPRD DATA
Gielen V1, Calado F2, Balas B2, Proenca CC3, Bruce Wirta S4, McMahon P5, Lucrezi G6, Richards C5, Croft D1
1Novartis Pharmaceuticals Ltd, Surrey, UK, 2Novartis Pharma AG, Basel, Switzerland, 3Wellmera AG, Basel, Switzerland, 4Novartis Sweden AB, Stockholm, Sweden, 5QuintilesIMS UK, London, UK, 6QuintilesIMS Switzerland, Basel, Switzerland

PHS112
E3
AN ECONOMIC EVALUATION OF 'DELIVERING ASSISTED LIVING LIFESTYLES AT SCALE’ (DALLAS)
Baba C1, Grieve E2, Mcintosh E1
1University of Glasgow, Glasgow, UK, 2Glasgow, Glasgow, UK

PHS113
E4
EVIDENCE SYNTHESES ON THE ECONOMIC VALUE OF HOSPITAL ANTIMICROBIAL STEWARDSHIP PROGRAMS [ASPS] – A CALL TO ACTION
Nathwani D1, Varghese D2, Lesher B2, Stephens JM2, Ansari W3, Charbonneau C4
1Ninewells Hospital & Medical School, Dundee, UK, 2Pharmerit International, Bethesda, MD, USA, 3Pfizer Inc, New York, NY, USA, 4Pfizer P.I.O., Paris, France

PHS114
E5
USE OF HEALTHCARE RESOURCES AND ASSOCIATED COSTS OF IDIOPATHIC PULMONARY FIBROSIS IN SPAIN: A REAL-LIFE STUDY
Sicras-Mainar A1, Somiedo Gutiérrez Md2, Navarro-Artieda R3, Arroyo Rivera MI4
1Red de Investigación en Servicios Sanitarios (Fundación REDISS), Barcelona, Spain, 2Medical Department, Roche Farma, Madrid, Spain, 3Documentación Médica,Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain, 4Payer Evidence & Health Economics Unit, Roche Farma., Madrid, Spain

PHS115
E6
HEALTH CARE CONSUMPTION AND HRQOL IN SEVERE ASTHMA IN SWEDEN
Jansson S1, Backman H1, Andersson M2, Telg G2, Lundbäck B3, Rönmark E1
1Umeå University, Umeå, Sweden, 2AstraZeneca Nordic-Baltic, Södertälje, Sweden, 3University of Gothenburg, Gothenburg, Sweden

PHS116
E7
ANALYSIS OF THE BEHAVIOR OF THE EXPENDITURE CURVE IN ONCOLOGY AND OTHER CAUSES OF DEATH IN THE LAST 5 YEARS OF LIFE – BRAZIL REAL-WORLD HEALTH CARE DATA
Reis Neto JP, Busch JM
Souza Marques University, Rio de Janeiro, Brazil

PHS117
E8
HEALTH CARE UTILIZATION ASSOCIATED WITH POLYPHARMACY IN PATIENTS WITH MULTIPLE SCLEROSIS
Rojanasarot S1, Carlson AM2
1College of Pharmacy, University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

PHS118
E9
WITHDRAWN

PHS119
E10
HEALTH SERVICE IMPLICATIONS OF THE IMPLEMENTATION OF AN EARLY DISCHARGE STRATEGY FOR PATIENTS ADMITTED IN INFECTIOUS DISEASES DEPARTMENTS IN SOUTHERN EUROPE
Restelli U1, Bonfanti M1, Rizzardini G2, Moreno Guillén S3, Grau Cerrato S4, Metallidis S5, Pacelli V1, Soro M6, Croce D1
1LIUC University, Castellanza, Italy, 2“Luigi Sacco” Hospital, Milan, Italy, 3Hospital Ramón y Cajal, Madrid, Spain, 4Hospital del Mar, Barcelona, Spain, 5Aristotle University of Thessaloniki, Thessaloniki, Greece, 6Angelini Pharmaceutical, S. Palomba – Pomezia (RM), Italy

PHS120
E11
SPATIAL DYNAMICS OF PSYCHIATRIC DISEASE HOSPITALIZED PATIENTS - REHOSPITALIZATION SIMULATION FOCUSSING ON DIABETES COMORBIDITY AND REGIONAL HEALTH SERVICES IN THREE EUROPEAN REGIONS OVER THE NEXT DECADES
Zauner G1, Urach C2, Bicher M3, Endel F4, Sprah L5
1dwh GmbH, Vienna, Austria, 2DEXHELPP, Vienna, Austria, 3Technical University, Institute for Analysis and Scientific Computing, Vienna, Austria, 4IMEHPS.research, Vienna, Austria, 5Research Centre of the Slovenian Academy of Sciences and Arts, Ljubljana, Slovenia

PHS121
E12
QUANTIFYING STANDARD OF CARE (SOC) HOSPITAL-RELATED RESOURCE UTILISATION FOR METASTATIC UVEAL MELANOMA (MUM) PATIENTS IN NHS ENGLAND (NHSE) USING THE HOSPITAL EPISODES STATISTICS (HES) DATASET
Cheng C1, Alamgir G2, Adams EJ1, Schwenkglenks M3, Toward T4
1Aquarius Population Health Limited, London, UK, 2Health iQ Ltd, London, UK, 3European Center of Pharmaceutical Medicine - University of Basel, Basel, Switzerland, 4Immunocore Limited, Abingdon, UK

PHS122
E13
DESCRIPTION OF THE CHINESE HEALTH CARE SYSTEM AFTER THE HEALTH CARE REFORM
Kerner Á1, Csákvári T2, Betlehem J1, Molics B1, Danku N1, Endrei D1, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

PHS123
E14
SCHOOL COMMUNITIES’ PARTICIPATION IN HEALTH PROMOTION PROCESS IN LITHUANIA
Maceinaite R, Surkiene G
Vilnius University, Vilnius, Lithuania

PHS124
E15
WITHDRAWN

PHS125
E16
INVESTING IN SKILLED SPECIALISTS TO GROW HOSPITAL INFRASTRUCTURE AND IMPROVE QUALITY
Padula WV1, Nagarajan M1, Davidson PM2, Pronovost PJ3
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins School of Nursing, Baltimore, MD, USA, 3Johns Hopkins Medicine, Baltimore, MD, USA

PHS126
E17
EFFECTS OF AVAILABILITY OF ESSENTIAL MEDICINES LIST ON SELLECTED DOMAINS OF PHARMACY SERVICES IN A NATIONAL HEALTH INSURANCE SCHEME (NHIS) ACCREDITED PHARMACY OF A UNIVERSITY TEACHING HOSPITAL IN NIGERIA ; AN INTERVENTION STUDY
Ele G1, Ogbonna B2
1Department of Pharmacy NAUTH, Nnewi, Nigeria, 2Nnamdi Azikiwe University Awka, Nigeria, Awka, Nigeria

PHS127
E18
PALLIATIVE CARE SERVICES IN ROMANIA- ANALYSIS OF UTILIZATION, FUNDING AND COVERAGE
Vajasdi H
ASSOCIATION VEHMED FOR HEALTH, CLUJ county, Romania

PHS128
E19
EFFECTIVENESS OF IDENTIFYING A CANCER PATIENT IN THE HOSPITAL SECTOR IN NORTHERN-NORWAY - ANALYSES BASED ON UPDATED REGIONAL PERFORMANCE DATABASE
Totth A1, Skjemstad ES1, Frøyshov HM1, Storjord T2, Norum J3, Høymork SC1
1Northern Norway Regional Health Authority Trust, Bodø, Norway, 2University Hospital of North Norway, Tromsø, Norway, 3UiT-The Arctic University of Norway, Tromsø, Norway

PHS129
E20
COST-EFFECTIVENESS ANALYSIS OF MEDICATION REVIEW INTERVENTIONS: A REVIEW OF LITERATURES
Akazawa M
Meiji Pharmaceutical University, Tokyo, Japan

PHS130
E21
PUBLIC HOSPITAL SUPPLY CHAIN: CURRENT VIEW AND CRITICAL ISSUES IN ITALY.
Triulzi I1, Antonel A2, Rossi E2, Turchetti G1
1Scuola Superiore Sant'Anna, Pisa, Italy, 2Logplus, Magenta, Italy

PHS131
E22
IMPROPER MEDICATION USE BY THE AGED POPULATION IN BAHRIA TOWN, LAHORE, PUNJAB, PAKISTAN
Shaukat A
Akhtar Saeed College of Pharmaceutical Sciences, Lahore, Pakistan

PHS132
E23
MUNICIPAL HEALTH CONFERENCES IN THE STATE OF BADEN-WUERTTEMBERG, GERMANY – READY FOR INITIATING AND STEERING PRIMARY HEALTH CARE PROVISIONS AT COMMUNITY LEVEL?
Dröschel D1, Vollmer L2, Walzer S2, Pimperl A3
1MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 2MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 3OptiMedis AG, Hamburg, Germany

PHS133
E24
ANALYSIS OF THE REIMBURSEMENT AMOUNT AND THE ACTUAL COSTS FOR INFUSION OF IMMUNOBIOLOGICS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM
Assunção-Costa LA1, Nascimento HF2, Pinto CR3, Alcantara A1, Silva RO4, Salles MM4, Valli CG4, Lemos AC1
1Federal University of Bahia, Salvador, Brazil, 2Hospital Universitário Prof. Edgard Santos - HUPES, Salvador, Brazil, 3Southwestern Bahia State University, Jequié, Brazil, 4Hospital Universitário Prof, Edgard Santos, Salvador, Brazil

PHS134
E25
DEVELOPMENT OF A DESCRIPTIVE SYSTEM FOR MEASURING PATIENT EXPERIENCE
Singh J1, Pokhrel S1, Coyle D2, Longworth L3
1Brunel University London, London, UK, 2Brunel University London, Lodon, UK, 3PHMR Ltd, London, UK

PHS135
E26
WITHDRAWN

PHS136
E27
EMERGENCY DEPARTMENT USE AMONG AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE PATIENTS IN THE US
Clark LA1, Patel R1, Blanchette CM2, Noone JM2, Zenarosa GL1, Howden R1
1University of North Carolina at Charlotte, Charlotte, NC, USA, 2Precision Health Economics, Davidson, NC, USA

PHS137
F1
ALTERNATIVE SOURCES FOR HEALTH CARE FUNDING: PUBLIC HEALTH TAXES IN HUNGARY BETWEEN 2011-2016
Csákvári T1, Vajda R2, Kerner Á2, Molics B2, Endrei D2, Sebestyén A2, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary

PHS138
F2
COMPARISON OF WOMEN’S HEALTH CARE IN GERMANY, AUSTRIA AND SWITZERLAND REGARDING SURGICAL THERAPY OPTIONS FOR PATIENTS WITH ABNORMAL UTERINE BLEEDING
Schareck T, Schubert T, Vogelmann T
LinkCare GmbH, Stuttgart, Germany

PHS139
F3
STRUCTURAL CHANGE IN THE HUNGARIAN HEALTH CARE SYSTEM
Dozsa C
University of Miskolc, Verőce, Hungary

PHS140
F4
PERCEIVED SERVICE QUALITY AND PATIENT SATISFACTION AT PHARMACY DEPARTMENT IN YOGYAKARTA, INDONESIA
Zulkarnain AK1, Kristina SA2, Saraswati MS2
1Universitas Gadjah Mada, Yogyakarta, Indonesia, 2Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia

PHS141
F5
ANALYSIS OF EPIDEMIOLOGICAL DATA ON BURDEN DISEASE IN EUROPE
SatayevaL.G., SagantayevaS.Kh., Mirzabayeva N.A., Shopabaeva A. L
Kazakchstan National Medical University name Asfendiarov, Almaty, Kazakhstan

PHS142
F6
CHARACTERIZATION OF LOW DENSITY LIPOPROTEIN (LDL) LEVELS IN PATIENTS DIAGNOSED WITH ARTERIAL HYPERTENSION IN COLOMBIAN POPULATION IN THE YEAR 2016
Isaza D1, Acuña L2, Bryón A3, Gutiérrez B4, Sanchez P2, Soler L5, Merchan A6, Ruiz A7, Aschner P7
1Fundacion Cardio Infantil, Bogota, Colombia, 2Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 3HEORT - Health Economics & Outcomes Research Team, Bogota, Colombia, 4HEORT, Bogota, Colombia, 5Risk Management Cordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia, 6Shaio, Bogota, Colombia, 7Pontificia Universidad Javeriana Medical School, Bogota, Colombia

PHS143
F7
CHARACTERIZATION OF LOW DENSITY LIPOPROTEIN (LDL) LEVELS IN PATIENTS DIAGNOSED WITH DIABETES MELLITUS IN COLOMBIAN POPULATION IN THE YEAR 2016
Aschner P1, Acuña L2, Bryón A3, Gutiérrez B4, Sanchez P2, Soler L5, Isaza D6, Merchan A7, Ruiz A1
1Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 2Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 3HEORT - Health Economics & Outcomes Research Team, Bogota, Colombia, 4HEORT, Bogota, Colombia, 5Risk Management Cordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia, 6Fundacion Cardio Infantil, Bogota, Colombia, 7Shaio, Bogota, Colombia

PHS144
F8
CHARACTERIZATION OF LOW DENSITY LIPOPROTEIN (LDL) LEVELS IN PATIENTS DIAGNOSED WITH CRONIC KIDNEY DISEASE IN COLOMBIAN POPULATION IN THE YEAR 2016
Acuña L1, Bryón A2, Gutiérrez B3, Sanchez P1, Soler L4, Aschner P5, Ruiz A5, Isaza D6, Merchan A7
1Fondo Colombiano de Enfermedades de Alto Costo, Bogotá, Colombia, 2HEORT - Health Economics & Outcomes Research Team, Bogota, Colombia, 3HEORT, Bogota, Colombia, 4Risk Management Cordinator, Fondo Colombiano de Enfermedades de Alto Costo, Bogota, Colombia, 5Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 6Fundacion Cardio Infantil, Bogota, Colombia, 7Shaio, Bogota, Colombia

PHS145
F9
CLOSING THE EVIDENCE GAP FOR ORPHAN DRUGS: DO GERMAN REGULATORY REQUIREMENTS GIVE INCENTIVES FOR HIGH LEVEL EVIDENCE GENERATION?
Babac A, Greiner R, Bonduelle D
QuintilesIMS, Munich, Germany

PHS146
WITHDRAWN

PHS147
F10
TITLE: MULTI-DISCIPLINARY DECISION MAKING IN GENERAL PRACTICE- A CASE STUDY OF SWITCHING BETWEEN ORAL ANTICOAGULANTS
Kirby A, Murphy A, Bradley C
University College Cork, Cork, Ireland

PHS148
F11
IMPACT OF LIFESTYLE EDUCATION AND PHARMACIST INTERVENTION OF DRUG-RELATED PROBLEMS ON ELDERS AT HIGH RISK OF HAVING DEMENTIA
Lee VW, Tang VL, Ti M, Fong F, Ngai L, Lam A
The Chinese University of Hong Kong, Shatin, Hong Kong

PHS149
F12
PROSPECTIVE EVALUATION OF PATIENT-CENTERED CARE IN SHORT-TERM CANCER SURVIVORS, AT ONE AND TWO YEARS POST TREATMENT, THROUGH THE PATIENT ASSESSMENT OF CHRONIC ILLNESS CARE QUESTIONNAIRE.
Escobar A1, Bilbao A2, Perez-Ruiz E3, Rueda A4, Trujillo-Martin Md5
1Hospital Universitario Basurto. REDISSEC, Bilbao, Spain, 2Research Unit, Basurto University Hospital (Osakidetza) – Health Service Research Network on Chronic Diseases (REDISSEC), Bilbao, Spain, 3. Agencia Sanitaria Costa del Sol. Marbella. REDISSEC, Marbella, Malaga, Spain, 4Agencia Sanitaria Costa del Sol. REDISSEC, Marbella, Spain, 5Servicio de Evaluación y Planificación. REDISSEC, Tenerife, Spain

PHS150
F13
FAST-TRACK MEDICATION REFILL (FTMR) SERVICE COULD BE MORE COST-EFFECTIVE THAN THE CURRENT MODEL OF CARE IN HONG KONG
Lee VW, Kwan WH, Ko XC, Yan BP
The Chinese University of Hong Kong, Shatin, Hong Kong

PHS151
F14
A PILOT STUDY ABOUT THE APPROPRIATENESS OF THE BREAST CANCER CARE PATHWAY IN A LOCAL HEALTH AUTHORITY ASL CN2 (PIEDMONT, ALBA BRA-ITALY) BASED ON E.PIC.A. (ECONOMIC APPROPRIATENESS OF AN INTEGRATED CARE PATHWAY) PROTOCOL
Ricotti A1, Ortega C1, Brioschi E2, Canavese P2, Pierini A2, Cassissa G1, Bono D1, Bertetto O3, Messori Ioli G1
1ASL CN2, Alba, Italy, 2Roche SpA, Monza, Italy, 3Dipartimento Interaziendale Interregionale Rete Oncologica Piemonte Valle D’Aosta, Turin, Italy

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.